CapyFin

Calendar Reports

Search for a symbol...

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2026 CapyFin. All rights reserved.

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Aclaris Therapeutics Fiscal Q1 2022 Earnings Report - CapyFin

Aclaris Therapeutics

ACRS · NASDAQ🇺🇸

Overview Earnings

Dividends Seasonality Metrics

Q3 2025 -4.70%Q2 2025 +0.65%Q1 2025 -0.78%Q4 2024 -7.14%Q3 2024 +10.36%Q2 2024 -4.10%Q1 2024 -6.87%Q4 2023 -1.65%Q3 2023 +0.93%Q2 2023 -12.08%Q1 2023 -7.80%Q4 2022 -4.89%Q3 2022 +4.31%Q2 2022 +18.10%Q1 2022 -8.88%Q4 2021 +14.31%Q3 2021 -12.39%Q2 2021 +4.12%Q1 2021 -2.18%Q4 2020 +7.79%Q3 2020 +7.01%Q2 2020 +11.28%Q1 2020 +12.70%Q4 2019 -13.99%Q3 2019 +20.37%Q2 2019 -11.76%Q1 2019 -11.23%Q4 2018 +22.74%Q3 2018 -1.80%Q2 2018 -4.59%Q1 2018 -0.50%Q4 2017 -6.67%Q3 2017 -5.66%Q2 2017 -0.11%Q1 2017 +6.30%Q4 2016 -4.86%Q3 2016 -1.04%Q2 2016 +3.10%Q1 2016 -15.27%Q4 2015 -3.90%Q3 2015 +5.79%Q2 2015 Q4 2014 Q3 2014 Q2 2014

May 10, 2022

•

Mar 31, 2022

Aclaris Therapeutics Q1 2022 Earnings Report

Previous year: $1.78M

Previous year: -$0.57

Previous year: $575K

Cash and Equivalents

Previous year: $35.3M

Previous year: $161M

Aclaris Therapeutics

Unlock previous datapoints

Aclaris Therapeutics

Unlock previous datapoints

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Company Overview

Full financial data and analysis

View Aclaris Therapeutics